Abstract
Osteoarthritis (OA) is a degenerative joint disease that causes persistent joint pain and stiffness of mainly the large peripheral weight-bearing joints. It is a leading cause of functional disability and poor quality of life. Various modalities of therapy are recommended by different research organizations at different stages of OA including non-pharmacological, pharmacological, and surgical interventions. Intra-articular injections of hyaluronic acid (HA) is widely used for over three decades in the treatment of OA. However controversies exist regarding its safety and efficacy, the number of injections and courses, type of preparation, duration of its effects, and combining it with other drugs or molecules. This study aimed to review the most recent data available in the published literature to address these.
Electronic databases like Medline, Embase, ProQuest, and Google Scholar were searched for articles using keywords, intraarticular injections, hyaluronic acid, and osteoarthritis knee. The review was carried out as per PRISMA guidelines.
Thirty-eight randomized control trials (RCTs) investigating the efficacy and safety of intra-articular injection of HA were included in the systematic review. Out of the 38 studies, 22 (57.9%) were double-blind, eight (21%) single-blind, three (7.9%) non-blind, four (10%) with simple randomization, and one (2.7%) was open-labeled. Total 5,025 patients were included in these studies. The mean age of the patients was 60.28 years and the osteoarthritis grade of the knee joint was 1 to 3. HA was studied as a test preparation in 19 (50%) while in another 19 (50%) it was studied as a control. In 24 (63.2%) studies, HA was used as high molecular weight preparation in eight (21%) as low molecular weight preparation while in six studies the information was not available. HA was used as a standalone preparation in 31 studies, in two studies it was injected with platelet-rich plasma (PRP) and with either low-level laser therapy (LLLT), triamcinolone (TA), betamethasone (CS), poly deoxyribonucleotide (PDRN) or dexamethasone (DX) in one study each. In the majority of the studies, HA was given as a single injection (52.6% studies) or weekly three injections (28.9% studies). In 13.2 %, it was given as weekly 5 injections and in 5.3% as weekly two injections.
IA-HA injections have a limited role in the treatment of knee osteoarthritis in those patients who do not have sufficient pain relief with topical or oral medication and physical therapy. It is safe and effective except for minor side effects such as local pain and swelling lasting for a few days. Severe allergic reactions are extremely rare. They provide adequate pain relief and functional improvement for up to six months irrespective of a number of injections and type of preparations used. The combination formulations with corticosteroids or PRP or MSCs show better results than HA alone. Combining HA with newer molecules such as peptides or diclofenac for sustained and disease-modifying effects requires more studies in the future.
Keywords: role and effectiveness, knee osteoarthritis, sodium hyaluronate, hyaluronic acid, intra-articular injection
Introduction and background
Osteoarthritis (OA) is a degenerative joint disease that most commonly affects the lower extremities’ large peripheral weight-bearing joints [1]. OA is one of the leading causes of functional impairment in the United States, affecting an estimated 22.7 million individuals [2]. It affects the quality of life by causing persistent pain, stiffness, and reduced mobility of the afflicted joints, as well as physical and/or mental co-morbidity [3]. It will boost healthcare spending, which is anticipated to be roughly $ 128 billion in the United States [4].
Because of its vast complexity and interplay of various biological factors such as genetic alterations, sex hormone deficit, and aging, OA is still poorly understood [5]. Many recent studies have focused on molecular markers that have been linked to chondrocyte senescence caused by stress [6]. Chondrosenescence is a term used to describe the age-related decline in chondrocyte function [7]. A core set of evidence-based therapeutic modalities has been created, according to the OA Research Society International (OARSI) Guidelines and recommendations for OA care [8]. These modalities include non-pharmacological approaches such as patient education and awareness, physical activity, and rehabilitation aids; as well as pharmacological modalities such as acetaminophen prescriptions, and non-selective NSAIDs (Nonsteroidal anti-inflammatory drugs), selective COX-2 inhibitors, and even opioid prescription. The most often recommended OA medications are NSAIDs [9]. Despite the fact that NSAIDs’, have been shown to be useful in the treatment of pain, long-term usage is linked to the risk of serious side effects. Furthermore, due to pharmacogenomics interactions, their tailored response is quite heterogenous [9].
Glucosamine and chondroitin, intra-articular injections of viscosupplements, corticosteroids, and platelet-rich plasma (PRP) are some of the additional non-operative treatment options [8]. Surprisingly, reduction in BMI, physical treatment, such as mind-body exercises, strength training activities, and aerobic workouts, have all showed promise in improving OA prognosis when patients follow their physical therapy routine regularly [10]. Table 1 outlines the current guidelines for OA treatment regimens from several international associations [11,12].
Table 1. Pharmacological and procedural recommendations for treatment of knee osteoarthritis.
Society | Recommended | Inconclusive | Not recommended |
American Academy of Orthopedic Surgeons | Topical NSAIDs Oral NSAIDs Tramadol | Acetaminophen Nontramadol opioids I-CS I-PRP | Chondroitin Glucosamine I-HA |
Osteoarthritis Research Society International | Topical NSAIDs Capsaicin Acetaminophen (in patients without comorbidities) Oral NSAIDs ( in patients without comorbidities) SNRI (i.e. duloxetine in patient without comorbidities) I-CS | Chondroitin (for symptom relief) Glucosamine (for symptom relief) Opioids I-HA | Chondroitin (for disease modification) Glucosamine (for disease modification) |
American college of Rheumatology | Topical NSAIDs Acetaminophen Oral NSAIDs Tramadol I-CS | SNRIs (i.e. duloxetine) Nontramadol opioids I-HA | Topical capsaicin Glucosamine Chondroitin |
In the last few decades, there has been an increasing trend to use intra-articular injections of corticosteroids, analgesics/anti-inflammatory drugs, polymerized collagen, anti-cytokine drugs, or hyaluronic acid as alternative modalities to maximize the local effect while minimizing systemic side effects [13]. Since its approval in Japan and Italy in 1987-1988, intra-articular (IA) injections of hyaluronic acid (HA) have been frequently utilized. Even after successful use of IA-HA for over three decades, controversies still exist regarding its safety, efficacy, number of injections, type of preparation, duration of its effects and combining it with other drugs or molecules. This systematic review aims to appraise the most recent clinical data available on I-HA therapy in patients with KOA. The objective of this systematic review is, 1) does I-HA has any role in the treatment of Knee OA? 2) is it safe and effective?
Review
Methods
Study Design and Search Strategy
The review was performed as per the PRISMA guidelines. The search was carried out in the databases such as Medline, Embase ProQuest and Google scholar. Keywords like hyaluronic acid, hyaluronate injection, and osteoarthritis knee were used individually and in combination for the search.
Study Criteria
All randomized control trials (RCTs) investigating the efficacy and safety on intra-articular injection of HA from January 2015 to December 2021 were included in the review. Articles published in languages other than English, review articles, meta-analyses, book chapters, and editorials were not included in the review. The study selection process is represented in Figure 1.
Search Results
The literature search yielded 1,146 articles. Out of which 225 articles removed, as they were duplicate articles. Remaining 921 articles screened further for appropriateness. Further 677 articles excluded from the study as, they were not relevant or not published in English language. Out of remaining 244 articles, 206 articles excluded from the study, as these were review articles or book chapters or meta-analysis. Thirty-eight studies met our inclusion criteria were included in the review. Quality assessment of the trials included in the review was done using Cochrane risk-of-bias tool for randomized trials (version 2).
Studies’ Characteristics
Out of the 38 studies, 22 (57.9%) were double blind; 8 (21%) single blind, 3 (7.9%) non-blind, 4 (10%) with simple randomization and 1 (2.7%) was open labelled (Table 2).
Table 2. Study distribution, patients and injections characteristics.
Studies | ||||||||
2015 | 2016 | 2017 | 2018 | 2019 | 2020 | TOTAL | ||
RCT-DB | 3 | 5 | 4 | 6 | 4 | 0 | 22 (57.9%) | |
RCT-SB | 0 | 0 | 2 | 0 | 3 | 3 | 08 (21%) | |
RCT-NB | 0 | 1 | 1 | 1 | 0 | 0 | 03 (7.9%) | |
RCT-SR | 0 | 0 | 2 | 0 | 1 | 1 | 04 (10.5%) | |
RCT-OL | 0 | 0 | 0 | 0 | 1 | 0 | 01 (2.7%) | |
TOTAL | 3 | 6 | 9 | 7 | 9 | 4 | 38 (100%) | |
Patients’ characteristics | ||||||||
No. of patients | 628 | 701 | 665 | 1300 | 1426 | 305 | 5025 | |
Mean age (years) | 62.5 | 61.4 | 60.85 | 58.28 | 59.44 | 59.25 | 60.28(mean) | |
OA grade (KL) | 1-3 | 1-3 | 1-3 | 1-3 | 1-3 | 1-3 | ||
Injections characteristics | ||||||||
No. of injections | 1 | 2 | 2 | 5 | 4 | 5 | 2 | 20 (56.6%) |
2 | 0 | 0 | 1 | 1 | 0 | 0 | 02 (5.3%) | |
3 | 1 | 3 | 1 | 1 | 4 | 1 | 11 (28.9%) | |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 00 (0.0%) | |
5 | 1 | 2 | 0 | 1 | 0 | 1 | 05 (13.2%) | |
HA preparations | LMW | 1 | 2 | 1 | 1 | 1 | 2 | 08 (21%) |
HMW | 2 | 4 | 5 | 4 | 8 | 1 | 24 (63.2%) | |
NA | 1 | 1 | 1 | 2 | 0 | 1 | 06 (15.8%) | |
HA used as | SP | 4 | 3 | 4 | 2 | 4 | 2 | 19 (50%) |
Control | 0 | 4 | 3 | 5 | 5 | 2 | 19 (50%) |
Total 5,025 patients were included in these studies. The mean age of the patients was 60.28 years and osteoarthritis grade of the knee joint was 1 to 3 (Kelly-green-Lawrence grade) (Table 2).
Out of 38 studies, HA was studied as a test preparation in 19(50%) while in another 19(50%) it was studied as a control. In 24(63.2%) studies HA was used as high molecular weight preparation in eight (21%) as low molecular weight preparation while in six studies the information was not available. HA was used as a standalone preparation in 31 studies, in two studies it was injected with platelet rich plasma (PRP) and with either low-level laser therapy (LLLT), triamcinolone (TA), betamethasone (CS), poly deoxyribonucleotide (PDRN) or dexamethasone (DX) in one study each. In majority of the studies, HA was given as a single injection (52.6% studies) or weekly three injections (28.9% studies). In 13.2 %, it was given as weekly 5 injections and in 5.3% as weekly two injections (Table 2). The details of characteristics of studies included in the systematic review are represented in Table 2.
The minimum follow up of the patients was six weeks and maximum of four years with an average of 26 months for majority of the studies. The WOMAC (Western Ontario and McMaster university osteoarthritis index) score was used as an outcome measure in all studies. The other outcome measures assessed in some studies were knee and osteoarthritis outcome system (KOOS), European quality of life scale (EUROQoL), Knee quality of life (KQoL), Lequesne knee index (LKI), stair climb test (SCT), knee society score (KSS), patient global assessment (PGA), patient reported outcome (PRO), Japanese osteoarthritis measure (JKOM), visual analog scale (VAS), and Health assessment questionnaire (HAQ).
All of the studies reportedly concluded that intra-articular injections of HA have resulted in clinical improvement over baseline pain, stiffness and function up to three to six months. The improvement was more rapid when HA was combined with corticosteroid and more sustained when combined with PRP or BM-MSC. The most common AEs reported were arthralgia, join swelling, joint stiffness and back pain.
Discussion
Osteoarthritis (OA) is a degenerative joint disease that most commonly affects the lower extremities’ mainly large peripheral weight bearing joints. The current multimodal knowledge of OA incorporates trauma, mechanical forces, biochemical cartilage degradation, inflammation, and metabolic derangements in contrast to the idea that OA is just a degenerative process [14].
We may continue to target our treatments on stopping OA at the cause rather than relieving pain with analgesic, as we understand more about the pathophysiology of OA. Various evidence-based methods of therapy, including non-pharmacological, pharmacological and surgical are advised by various research bodies at various phases of osteoarthritis. In individuals, who do not react well to oral or topical medicine and physical therapy, intra-articular injectable treatments with corticosteroids, viscosupplements, platelet rich plasma (PRP) and stem cells are recommended. Intra articular HA has been utilized widely to treat symptomatic knee OA over three decades.
Hyaluronic acid physiology in synovial fluid of joint
Hyaluronate is a high molecular weight, widely distributed substance found in the cartilage and synovial fluid. It’s made up of alternating N-acetyl d-glucosamine and d-glucuronic acid residues connected by ß(1-4) and ß(1-3) bonds and has a molecular mass of 6,500 to 10,900 kDa [15]. It functions as a lubricant, a scavenger for free radicals, and a regulator of cellular activity including protein binding. The endogenous HA in the joint depolymerizes from a high molecular weight (6,500-10,900 kDa) to a lower molecular weight (2,700-4,500 kDa) as OA progresses, reducing the mechanical and viscoelastic properties of the synovial fluid in the affected joint [15,16]. Exogenous HA injections have therefore been employed clinically to attenuate the macerated activities of OA patients’ depolymerized endogenous HA. Although the exogenous HA may not fully repair and replace the characteristics and activities of the synovial fluid’s depolymerized endogenous HA, it may provide enough pain relief through a variety of methods [16]. Synthesis of proteoglycan and/or glycosaminoglycan, anti-inflammatory action, and viscoelasticity maintenance are among these processes [16]. Exogenous HA has a varied reaction; one possible reason for the varying efficacy of HA therapies on OA patients is the levels of hyaluronidases in a patient’s synovial fluid. Hyaluronidases are a group of enzymes that degrade hyaluronic acid by cleaving the β(1-4) linkages of HA and fragmenting it into smaller fragments before degradation [17].
Hyaluronic acid and its preparations for treatment of OA
HA is given to OA patients in one of the two ways, by mouth or by local injection. Synvisc and Synvisc-One (Genzyme); Gel-One (Zimmer); Hyalgan (Fidia); Spartz FX (Bioventus); Orthovisc (Anika); Euflexxa (Savient); Monovisc (Anika Therapeutics) and Gel-Syn (Institute Biochimique SA) are some of the injectable HA formulations available for clinical usage [18]. They differ in many ways; mean molecular weight, molecular structure (linear, cross-linked or both), source (animal versus bacterial bio-fermentation using modified organisms), method of crosslinking, volume of injection (0.5-6.0 mL), concentration (0.8-30 mg/mL) and posology [19]. For many years, animal source was regarded a conventional source; however, modified bacterial source is now the primary source since it is connected with cheaper costs and fewer adverse effects [20]. The pain relieving action of the injected HA is assumed to be produced through a number of different mechanisms. These include increasing extracellular matrix protein synthesis, modifying inflammatory mediators to prevent degradation, limiting lymphocyte motility, and preserving cartilage thickness, area and surface smoothness [21]. However, further study is needed to comprehend the physiological effect of HA.
Human clinical studies involving hyaluronic acid
Several clinical trials have developed numerous HA formulations and investigated their effectiveness and safety throughout the last decade. Despite the fact that several studies have shown that intra-articular HA injection can be a good non-surgical treatment for OA and can delay the need for joint replacement, there is still debate over its clinical efficacy and long-term viability.
Altman et al. concluded in 2004 that Durold in the affected joint duct with very high molecular weight HA(100,000 kDa) is not beneficial and has no superiority over placebo treated groups in terms of The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) score and other efficacy parameters [22]. There is a wide range of responses to different injectable HA preparations; Johan et al. discovered that using of high molecular weight I-HA preparations resulted in clinically significant pain reduction [22]. In patients with knee OA, Lundsgaard et al. found no significant difference between the intra-articular injection of HA (Hylagan®; 6000 kDa) and injection of physiological saline [23]. When compared to I-CS, which offered the highest pain reduction during first four weeks after injection, Rodriquez-Merchan found that when compared to I-CS, which provided the most pain relief during the first 4 weeks post-injection, I-HA produced superior results at five and thirteen weeks, and that the enhanced impact lasted until 26 weeks [24]. Knee OA appears to be treated well and safely with repeated rounds of I-HA. The most prevalent adverse effect of repeated I-HA was joint swelling and arthralgia, according to a 2018 systemic evaluation of patients who had recurrent cycles of I-HA for up to 25 months [25].
Timing and duration of injection
One of the most contentious aspects of HA injection is when and how long it should be given, and if this has an influence on its efficacy and long-term viability. Cubukuc et al. compared Hylan G-F 20 and saline intra-articular injections three times a week in OA patients. They found that the HA group experienced optimal pain alleviation as early as the third week, and that functional improvement occurred by the eighth week [26]. Patrella et al. conducted a randomized controlled trial in 2006 to compare the effects of three vs six consecutive weekly HA injections. They showed that there are no variations in pain, function or patient satisfaction between 3 and 6 HA injections [27]. Huskisson et al. demonstrated in 1999 that 5 weekly intra-articular injections of sodium hyaluronate (Hyalgan A) resulted in a 6-month clinical improvement [28]. Another randomized controlled clinical trial found that that 5 weekly IA injections of HA (Hyalgan) in patients with knee OA offered long-term pain relief and improved patient function, and were at least as effective as continuous naproxen therapy for 26 weeks with fewer side effects [29].
Despite its success in KOA management, I-HA is contested, and there is no consensus among international recommendations on how to utilize it. We have tried to find the answer to these controversies by reviewing the most recent data of randomized controlled clinical trials of the last five years reporting the safety and efficacy of I-HA in KOA.
Efficacy and Safety
These clinical studies have investigated the safety and efficacy of I-HA in general [30-32].
and in different dose regimens of I-HA [33]. The preparations were used from various sources of I-HA - animal and non-animal [33,34] of low molecular weight (LMW) and high molecular weight (HMW) [35] of different structures - cross-linked and linear [36]. The different formulations of I-HA [37] were studied for safety and efficacy of I-HA in combination or in comparison with corticosteroids [37,38] collagen [39] bone marrow-derived mononuclear cells [40] umbilical cord-derived mesenchymal stromal cells [41] bone marrow mesenchymal stem cells [42] ozone therapy [43] polydeoxyribonucleotide [44] platelet-rich plasma [45,46] plasma rich in growth factor [47] amniotic suspension allograft [48] chondroitin [49] and N-acetyl cysteine [50]. All these trials conclude that I-HA is both safe and effective when used alone and in conjunction with other viscosupplements. Furthermore, they support I-HA’s therapeutic efficacy in reducing pain and improving function in patients with KOA. In trials comparing the safety and efficacy of I-HA to other viscosupplements, the vast majority of the studies found I-HA to be non-inferior to its competitors.
Single/Multiple Injections
A variety of I-HA formulations are currently on the market for the treatment of KOA. These preparations differ in origin, structure, molecular weights, concentrations and injected volume. The majority of I-HA preparations on the market today are multiple injection regimens; however, single injection I-HA has also been developed and is becoming more widely used in clinical practice. Zhang H et al. examined the effects of single and multiple injections of I-HA in KOA in a randomized multicenter study and found that single injections were non-inferior to multiple injections of I-HA in alleviating pain, knee stiffness, and increasing physical function over 18 and 26 weeks [33]. Baron et al. reported similar results showing that a single I-HA injection was clinically effective in the treatment of KOA [31]. Ha et al. found that a single injection of cross-linked hyaluronate was non-inferior to multiple injections of linear high molecular hyaluronate in reducing weight-bearing pain in symptomatic KOA [36]. These results indicate that number of I-HA injections may not have a significant difference in terms of effectiveness of the therapy.
HMW or LMW Preparations and Cross Linking
Over the years, several studies on I-HA with different molecular weights for the treatment of KOA have been published, with contradictory results, but favoring HMW HA. A similar study that compared the effectiveness of a HMW HA with a LMW HA preparation, found that both reduced pain, stiffness and function in patients with KOA in a similar way [35].
Another study comparing the efficacy of chemically cross-linked HA and avian-derived HA in KOA patients found that the chemically cross-linked HA was superior to avian-derived HA in lowering the VAS pain score and total Western Ontario and McMaster Universities Arthritis Index (WOMAC) score as well as in decreasing the Lequesne index score [34]. These findings imply that the source of I-HA may have an impact on the therapy’s efficacy.
Alone or in Combination With Other Drugs or Molecules
I-HA, alone or in conjunction with corticosteroids has been shown in studies to be safe and effective for the management of KOA. Petrella et al. showed that a single I-HA injection alone or in combination of triamcinolone was well tolerated and decreased pain associated with KOA in a prospective, multicenter, randomized study [37].
Maia et al. undertook another prospective randomized study to assess patient outcomes with intra-articular HA infiltration in conjunction with dexamethasone in treatment of KOA. The WOMAC overall score and sub scores for pain, stiffness, and function improved significantly with I-HA alone and in combination with dexamethasone. It also resulted in improvement of knee extensor and flexor strength [38].
In patients with KOA, a multicenter study testing the efficacy of a novel intra-articular combination of sodium hyaluronate- chondroitin sulfate found that the combination significantly improved pain severity and reduced analgesic use [49]. In a prospective, randomized research done by Yoon et al. combining intra-articular injection of polydeoxyribonucleotide with HA improved the efficiency of HA in enhancing knee joint functioning. All of these trials show that combination therapies with HA significantly enhances clinical outcomes in terms of pain and function in patients with KOA [44].
In Comparison With Other Injectable Therapies
In the majority of trials comparing I-HA to other viscosupplements in KOA, I-HA had similar results to its competitors. Martin et al. compared the safety and effectiveness of I-HA to MD-Knee, a collagen-containing product. The study’s findings revealed at three and six months after treatment, both I-HA and MD-knee groups had equal clinical outcomes in terms of improved function and pain reduction [39].
A six-month randomized clinical research comparing the benefits of ozone treatment with I-HA in KOA found that both groups saw equal reductions in total WOMAC score and improvements in pain, stiffness and function in both the groups [43]. A double-blind randomized controlled clinical trial comparing the intra-articular injections of Platelet-Rich Plasma (PRP) with HA in the treatment of KOA found that both arms saw similar pain and functional improvements [46]. Another study comparing the effectiveness of Plasma Rich in Growth Factor (PRGF) vs HA patients with symptomatic mild to moderate KOA found that both PRGF and HA, produced significant reductions in pain evaluated by VAS and significant improvement in WOMAC and Lequesne scores at six-month follow-up [47].
Ozcamdalli et al. evaluated intra-articular injections of HA and N-acetyl cysteine (NAC) in the treatment of KOA and found that both were equally efficient in reducing pain and enhancing function in KOA patients. In addition, combination preparations consisting of HA with diclofenac [51] and HA with polynucleotides have been found to significantly improve pain in patients with KOA [52]. All of these trials show that I-HA is not inferior to other viscosupplements in the treatment of KOA [50].
Duration of Symptomatic Relief and Disease Modifying Effect
Recently the disease modifying effects of I-HA in KOA have also been studied [30,53]. Henrotin et al. conducted an open labelled multicenter study to investigate the effect of I-HA on cartilage degradation biomarkers and found that I-HA had a favorable effect on type II collagen turnover and cartilage volume, indicating that I-HA may have a potential structure- modifying effect in KOA patients [30].
Limitations of this study
Studies included are of specific time period as we wanted to look for more recent data (Table 3). Studies published in languages other than English are not included.
Table 3. Characteristics of studies included in the systematic review.
Study Details | Patient’s Characteristics | Injection Characteristics | Outcome | ||||||||||
Sr. | Author | Year | Study type | Number | Mean age (Yrs.) | OA grade | HA brand | Molecular weight (KDa) | No. of injections | Comparison group | Outcome measures assessed | Follow up | Conclusion |
1 | Henrotin et al. [32] | 2017 | RCT-DB | 66 | 65 | 2-3 | Kartilage Cross (XLHA) | NA | 1 | Saline | Reduction in Coll2-1 | 90 days | Reduction in cartilage marker was significant |
2 | Zhang et al. [33] | 2015 | RCT-DB | 349 | 60 | 2-3 | Durolane | 90,000 | 1 | Artz (HA)- 5 inj. (620-1200 kDa) | WOMAC, GSA | 26 wks. | Effective and non-inferior |
3 | Yang et al. [34] | 2018 | RCT-DB | 258 | 64 | 2-3 | HYA-JOINT plus (CCH) | NA | 1 | Hylan G-F-20 (6000 kDa) | WOMAC, SLS, TUG | 3-6 months | Improvement. CCH group superior to ADH |
4 | Gigis et al. [35] | 2016 | RCT-DB | 80 | 67 | 2-4 | LMW | 1,000-1,500 | 5 | HMW/3 inj. (6,000-7,000) | VAS, WOMAC | 3 mn-1 yr | Significant improvement & no difference in groups |
5 | Ha et al. [36] | 2017 | RCT-DB | 266 | 62 | 1-3 | XLHA (Hyruan Plus) | ≥10,000 | 1 | HMWHA (3 inj) | WBP, WOMAC | 12 wks. | Effective and non-inferior, safe |
6 | Petrella et al. [37] | 2015 | RCT-DB | 98 | 59 | 2-3 | Hydros(Hydro-gel beads) | NA | 1 | Hydros-TA and Synvisc-one | WOMAC | 26 wks. | Clinical improvement |
7 | Aguiar et al. [38] | 2019 | RCT-DB | 44 | 57 | 1-2 | Orthovisc | 1,000-2,900 | 1 | HA+DX, DX alone | WOMAC, Flx & Ext. strength | 6 months | Significant improvement |
8 | Martin et al. [39] | 2016 | RCT-DB | 60 | 69 | 2-3 | Md-knee (collagen) | 600-1200 | 5 | Supartz (HA) | LKI, VAS, PKC | 3-6 months | Significant improvement both groups |
9 | Goncars et al. [40] | 2017 | RCT-SR | 56 | 58 | 2-3 | BM-MSCs | 800-1,500 | 1 | GO-ON (HA -3 inj) | KOOS, KSS | 3-12 months | Significant improvement more in BM-MSCs |
10 | Matas et al. [41] | 2018 | RCT-DB | 26 | 55 | 2-3 | UC-MSCs 2 dose (0-6 mn) | 90,000 | 2 | UC-MSCs-1 dose, Durolane | PGA, WOMAC | 52 wks | Improvement in all group. Sustained up to 12 month in UC-MSCs-2 |
11 | Espinosa [42] | 2016 | RCT-NB | 30 | 60 | 2-4 | BM-MSC-LD, BM-MSC-HD Plus HA | 1,500-2,000 | 1 | Hyalone (1,500-2,000 kDa) | VAS, WOMAC, MRI, X-ray | 3-12 months | Clinical improvement. Sustained up to 12 mon in BM-HSC-HD group |
12 | Raeissadat et al. [43] | 2018 | RCT-DB | 141 | 60 | 2-3 | Hyalgan | 500-730 | 3 | Ozone sol. | VAS, WOMAC (Persian version) | 6 months | Clinical improvement both groups. no diff |
13 | Yoon et al. [44] | 2019 | RCT-DB | 30 | 65 | 2-3 | HA+PDRN (polydeoxyriboneucleotide placenetex) | 1500-2000 | 3 | HA (Hylone plus) | VAS, WOMAC, KSS | 6 months | Effective and combination can be considered for OA treatment |
14 | Raeissadat et al. [45] | 2020 | RCT-SB | 102 | 58 | 2-3 | PRGF (2 inj.- 3 wks. apart) | 730 | 3 | HA (Hyalgan) | VAS, WOMAC, ADL, LKI | 6-12 months | Satisfactory improvement higher in PRGF group at 12 mon. |
15 | Montanez et al. [46] | 2016 | RCT-DB | 53 | 61 | 1-3 | PRP | 600-1,200 | 3 | Adant (HA) | VAS, KOOS, EUROQOL | 3-6 months | Clinical improvement both groups |
16 | Raeissadat et al. [47] | 2017 | RCT-SB | 69 | 59 | 2-3 | PRGF | 500-730 | 2 | Hyalgan (HA-3 inj) | VAS, WOMAC, LKI | 6 months | Equally effective |
17 | Farr et al. [48] | 2019 | RCT-SB | 200 | 55 | 2-3 | ASA (amniotic suspension allograft) | 1,000-2,900 | 1 | Monovisc (1,000-2,900), saline | PRO, KOOS, VAS, SANE | 3-6 months | Improvement, greater in ASA group |
18 | Ozcamdalli et al. [50] | 2017 | RCT-SB | 20 | 55 | 2-3 | Hyalan G-F 20 | 6,000 | 1 | NAC (1 inj) | VAS, WOMAC | 6 wks. | Effective. NAC reduces cartilage degradation markers |
19 | Ip [54] | 2015 | RCT-DB | 70 | 75 | 3 | Hyalgan+LLLT | 500-730 | 5 | Saline+PT+ Sham light irrad | WOMAC | Mean 7 yrs. | Prolongs longevity of knee joint |
20 | Strand et al. [55] | 2016 | RCT-DB | 350 | 61 | 1-3 | Gel-200 | NA | 1 | Retreatment after 13 wks. | WOMAC | 26 wks. | Effective and safe |
21 | Paterson et al. [56] | 2016 | RCT-DB | 23 | 51 | 2-3 | PA-PRP | 6,000 | 3 | Synvisc-one | VAS, KOOS, KQoL | 12 wks. | Improvement, more significant in PRP group |
22 | Cole et al. [57] | 2017 | RCT-DB | 111 | 56 | 1-3 | Synvisc | 6,000 | 3 | PRP | VAS, WOMAC, IKDC | 24 wks. | Significant improvement both groups |
23 | Lana et al. [58] | 2017 | RCT-DB | 105 | 61 | 1-3 | Euflexxa (HMW) | 2,400-3,600 | 3 | HA+PRP | VAS, WOMAC | 3-12 months | Improvement. More and sustained in HA+PRP group |
24 | Lee et al. [59] | 2017 | RCT-SR | 61 | 68 | 2-3 | ESWT (3 sessions) | 3,000 | 3 | HA | VAS, WOMAC, SCT | 1-3 | Significant improvement both group |
25 | Suppan et al. [60] | 2017 | RCT-NB | 127 | 59 | 1-3 | GO-ON (5mL) | 800-1,500 | 1 | GO-ON (HA -3 inj- 2.5ml) | WOMAC | 3 months | Good efficacy, tolerability and safety |
26 | Yu et al. [61] | 2018 | RCT-DB | 360 | 48 | NA | PRP | NA | 5 | HA, PRP+HA, Placebo | WOMAC, Karnofsky perfo | 52 wks. Post Trt. | Improvement significant in PRP+HA group |
27 | Lamo‑Espinosa et al. [62] | 2018 | RCT-NB LT | 27 | 60 | 2-4 | BM-MSCs-LD/HD +HA | 1,500-2,000 | 1 | HA alone (Hyalone) | VAS, WOMAC | 12-48 months | Safe and feasible with long term clinical improvement |
28 | Hangody et al. [63] | 2018 | RCT-DB | 368 | 58 | 1-3 | Cingal (HA+TA) | 1900 | 1 | Monovisc (1000-2900 kDa), saline | PGA, WOMAC | 26 WKS | Effective, immediate and LT relief with Cingal > 26 wks |
29 | Wang et al. [64] | 2018 | RCT-DB | 120 | 63 | 2-4 | HA+CS (betamethasone) | 600-1,500 | 1 | HMWHA | VAS, WOMAC | 6 months | Improvement, rapid in HA+CS group |
30 | Buendia et al. [65] | 2018 | RCT-SR | 106 | 56 | 1-2 | LP-PRP-1 | 90,000 | 1 | HA (Durolane), NSAID | VAS, WOMAC, MRI, X-RAY | 6-12 months | Improvement better in LP-PRP group at 52 wks. |
31 | Hermans et al. [66] | 2019 | RCT-OL | 156 | 54 | 1-3 | Hylan (G-F 20) | 6,000 | 3 | UC (usual care) | KOOS, PGA | 52 wks. | Effective |
32 | Maheu et al. [67] | 2019 | RCT-DB | 292 | 67 | 1-3 | Ostenil1 Plus | 1,000-,2000 | 1 | Hyalan G-F 20 | WOMAC | 6 months | Effective and non-inferior |
33 | Takamura et al. [68] | 2019 | RCT-SB | 311 | 61 | 1-3 | Gel-200 (XLHA) | >5,000 | 1 | Saline | VAS, WOMAC | 26 wks. | Effective and clinical improvement |
34 | Tavassoli et al. [69] | 2019 | RCT-SB | 95 | 63 | 1-2 | PRP-1 | 730 | 3 | PRP-2, HA-3 (Hyalgan) | VAS, WOMAC | 12 wks. | Improvement, PRP better than HA |
35 | Di Martino et al. [70] | 2019 | RCT-DB | 192 | 57 | 1-3 | PRP | 3,200 | 3 | Hylubrix (HA) | VAS, IKDC, EUROQoL | 24 mn & Mean 64 mn | Effective, not superior in PRP group |
36 | Bahrami et al. [71] | 2020 | RCT-SB | 90 | 56 | 2-3 | HMWHA (Arthromac) | NA | 1 | LMWHA (3 inj.) | VAS, WOMAC, LKI | 2-6 months | Remarkable improvement both group with no difference |
37 | Kesiktas et al [72] | 2020 | RCT-SR | 54 | 56 | 2-4 | Prostrolane (Peptide) | 1700-2100 | 1 | HA (Biometics), PRP | VAS, WOMAC, HAQ | 3 months | Significant improvement, better in peptide group |
38 | Mochizuki et al. [73] | 2020 | RCT-SB | 59 | 67 | 1-4 | Artz (LMWHA) | 620-1,200 | 5 | Suvenyl (IMMWHA ) (1500-3900) | VAS, JKOM | 6 wks. | Significant efficacy. No difference |
Conclusions
The IA-HA injections have a limited role in treatment of knee osteoarthritis. It is recommended to use in mild to moderate knee osteoarthritis in patients who do not have sufficient pain relief with topical or oral medication and physical therapy. Not used as first line therapy as it's expensive and has no data to shows improved efficacy. It is safe and effective except minor side effects such as local pain and swelling lasting for few days. Severe allergic reactions to the preparations are extremely are. They provide adequate pain relief and functional improvement but for limited period of time up to six months irrespective of number of injections and type of preparations used. The combination formulations with corticosteroids or PRP shows better results than HA alone. Combining HA with newer molecules such as peptides or diclofenac for sustained and disease-modifying effects, requires more studies in the future.
The content published in Cureus is the result of clinical experience and/or research by independent individuals or organizations. Cureus is not responsible for the scientific accuracy or reliability of data or conclusions published herein. All content published within Cureus is intended only for educational, research and reference purposes. Additionally, articles published within Cureus should not be deemed a suitable substitute for the advice of a qualified health care professional. Do not disregard or avoid professional medical advice due to content published within Cureus.
Footnotes
The authors have declared that no competing interests exist.
References
- 1.Osteoarthritis as an inflammatory disease (osteoarthritis is not osteoarthrosis!) Berenbaum F. Osteoarthritis Cartilage. 2013;21:16–21. doi: 10.1016/j.joca.2012.11.012. [DOI] [PubMed] [Google Scholar]
- 2.Prevalence of doctor-diagnosed arthritis and arthritis-attributable activity limitation — United States, 2010-2012. Barbour KE, Helmick CG, Theis KA, Murphy LB, Hootman JM, Brady TJ, Cheng YJ. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4585589/ MMWR Morb Mortal Wkly Rep. 2013;62:869–873. [PMC free article] [PubMed] [Google Scholar]
- 3.The burden of osteoarthritis: clinical and quality-of-life issues. Moskowitz RW. https://www.ajmc.com/view/a235_09sepmoskowitzs223to229. Am J Manag Care. 2009;15:223–229. [PubMed] [Google Scholar]
- 4.Socio-economic costs of osteoarthritis: a systematic review of cost-of-illness studies. Puig-Junoy J, Ruiz Zamora A. Semin Arthritis Rheum. 2015;44:531–541. doi: 10.1016/j.semarthrit.2014.10.012. [DOI] [PubMed] [Google Scholar]
- 5.Clinical settings in knee osteoarthritis: pathophysiology guides treatment. Herrero-Beaumont G, Roman-Blas JA, Bruyère O, et al. Maturitas. 2017;96:54–57. doi: 10.1016/j.maturitas.2016.11.013. [DOI] [PubMed] [Google Scholar]
- 6.OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Zhang W, Moskowitz RW, Nuki G, et al. Osteoarthritis Cartilage. 2008;16:137–162. doi: 10.1016/j.joca.2007.12.013. [DOI] [PubMed] [Google Scholar]
- 7.Osteoarthritis Fact Sheet. [ May; 2020 ];https://www.cdc.gov/arthritis/basics/osteoarthritis.htm 2020
- 8.The Ottawa panel clinical practice guidelines for the management of knee osteoarthritis. Part one: introduction, and mind-body exercise programs. Brosseau L, Taki J, Desjardins B, et al. Clin Rehabil. 2017;31:582–595. doi: 10.1177/0269215517691083. [DOI] [PubMed] [Google Scholar]
- 9.The Ottawa panel clinical practice guidelines for the management of knee osteoarthritis. Part three: aerobic exercise programs. Brosseau L, Taki J, Desjardins B, et al. Clin Rehabil. 2017;31:612–624. doi: 10.1177/0269215517691085. [DOI] [PubMed] [Google Scholar]
- 10.Effectiveness of non-steroidal anti-inflammatory drugs for the treatment of pain in knee and hip osteoarthritis: a network meta-analysis. da Costa BR, Reichenbach S, Keller N, Nartey L, Wandel S, Jüni P, Trelle S. Lancet (London, England) 2017;390:21–33. doi: 10.1016/S0140-6736(17)31744-0. [DOI] [PubMed] [Google Scholar]
- 11.American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Hochberg MC, Altman RD, April KT, et al. Arthritis Care Res (Hoboken) 2012;64:465–474. doi: 10.1002/acr.21596. [DOI] [PubMed] [Google Scholar]
- 12.The American Academy of Orthopaedic Surgeons evidence-based guideline on: treatment of osteoarthritis of the knee, 2nd edition. Jevsevar DS, Brown GA, Jones DL, et al. J Bone Joint Surg Am. 2013;95:1885–1886. doi: 10.2106/00004623-201310160-00010. [DOI] [PubMed] [Google Scholar]
- 13.The structure and function of hyaluronan: an overview. Laurent TC, Laurent UB, Fraser JR. Immunol Cell Biol. 1996;74:0–7. doi: 10.1038/icb.1996.32. [DOI] [PubMed] [Google Scholar]
- 14.Knee osteoarthritis: pathophysiology and current treatment modalities. Mora JC, Przkora R, Cruz-Almeida Y. J Pain Res. 2018;11:2189–2196. doi: 10.2147/JPR.S154002. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.The mechanism of action for hyaluronic acid treatment in the osteoarthritic knee: a systematic review. Altman RD, Manjoo A, Fierlinger A, Niazi F, Nicholls M. BMC Musculoskelet Disord. 2015;16:321. doi: 10.1186/s12891-015-0775-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Hyaluronidases: their genomics, structures, and mechanisms of action. Stern R, Jedrzejas MJ. Chem Rev. 2006;106:818–839. doi: 10.1021/cr050247k. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Intra-articular hyaluronan (hyaluronic acid) and hylans for the treatment of osteoarthritis: mechanisms of action. Moreland LW. Arthritis Res Ther. 2003;5:54–67. doi: 10.1186/ar623. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Low-molecular-weight hyaluronan permeates through human intestinal Caco-2 cell monolayers via the paracellular pathway. Hisada N, Satsu H, Mori A, Totsuka M, Kamei J, Nozawa T, Shimizu M. Biosci Biotechnol Biochem. 2008;72:1111–1114. doi: 10.1271/bbb.70748. [DOI] [PubMed] [Google Scholar]
- 19.Oral administration of high molecular weight hyaluronan (900 kDa) controls immune system via Toll-like receptor 4 in the intestinal epithelium. Asari A, Kanemitsu T, Kurihara H. J Biol Chem. 2010;285:24751–24758. doi: 10.1074/jbc.M110.104950. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Comparison of low-, moderate-, and high-molecular-weight hyaluronic acid injections in delaying time to knee surgery. Shewale AR, Barnes CL, Fischbach LA, Ounpraseuth ST, Painter JT, Martin BC. J Arthroplasty. 2017;32:2952–2957. doi: 10.1016/j.arth.2017.04.041. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Use of intraarticular hyaluronic acid in the management of knee osteoarthritis in clinical practice. Cooper C, Rannou F, Richette P, et al. Arthritis Care Res (Hoboken) 2017;69:1287–1296. doi: 10.1002/acr.23204. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Viscosupplementation in knee osteoarthritis: evidence revisited. Johal H, Devji T, Schemitsch EH, Bhandari M. JBJS Rev. 2016;4:0. doi: 10.2106/JBJS.RVW.15.00098. [DOI] [PubMed] [Google Scholar]
- 23.Clinical effects of intraarticular injection of high molecular weight hyaluronan (Orthovisc) in osteoarthritis of the knee: a randomized, controlled, multicenter trial. Neustadt D, Caldwell J, Bell M, Wade J, Gimbel J. https://www.jrheum.org/content/jrheum/32/10/1928.full.pdf. J Rheumatol. 2005;32:1928–1936. [PubMed] [Google Scholar]
- 24.Intra-articular injections of hyaluronic acid and other drugs in the knee joint. Rodriguez-Merchan EC. HSS J. 2013;9:180–182. doi: 10.1007/s11420-012-9320-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Efficacy and safety of repeated courses of hyaluronic acid injections for knee osteoarthritis: A systematic review. Altman R, Hackel J, Niazi F, Shaw P, Nicholls M. Semin Arthritis Rheum. 2018;48:168–175. doi: 10.1016/j.semarthrit.2018.01.009. [DOI] [PubMed] [Google Scholar]
- 26.Hylan G-F 20 efficacy on articular cartilage quality in patients with knee osteoarthritis: clinical and MRI assessment. Cubukçu D, Ardiç F, Karabulut N, Topuz O. Clin Rheumatol. 2005;24:336–341. doi: 10.1007/s10067-004-1043-z. [DOI] [PubMed] [Google Scholar]
- 27.Safety and efficacy of retreatment with a bioengineered hyaluronate for painful osteoarthritis of the knee: results of the open-label Extension Study of the FLEXX Trial. Altman RD, Rosen JE, Bloch DA, Hatoum HT. Osteoarthritis Cartilage. 2011;19:1169–1175. doi: 10.1016/j.joca.2011.07.001. [DOI] [PubMed] [Google Scholar]
- 28.Hyaluronic acid in the treatment of osteoarthritis of the knee. Huskisson EC, Donnelly S. Rheumatology (Oxford) 1999;38:602–607. doi: 10.1093/rheumatology/38.7.602. [DOI] [PubMed] [Google Scholar]
- 29.Clinical and cost outcomes from different hyaluronic acid treatments in patients with knee osteoarthritis: evidence from a US health plan claims database. Dasa V, DeKoven M, Sun K, Scott A, Lim S. Drugs Context. 2016;5:212296. doi: 10.7573/dic.212296. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Hyaluronan derivative HYMOVIS® increases cartilage volume and type ii collagen turnover in osteoarhritic knee: data from MOKHA study. Henrotin Y, Bannuru R, Malaise M, et al. BMC Musculoskelet Disord. 2019;20:293. doi: 10.1186/s12891-019-2667-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Hyaluronic acid single intra-articular injection in knee osteoarthritis: a multicenter open prospective study (art-one 75) with placebo post hoc comparison. Baron D, Flin C, Porterie J, Despaux J, Vincent P. Curr Ther Res Clin Exp. 2018;88:35–46. doi: 10.1016/j.curtheres.2018.04.001. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Reduction of the serum levels of a specific biomarker of cartilage degradation (Coll2-1) by hyaluronic acid (KARTILAGE® CROSS) compared to placebo in painful knee osteoarthritis patients: the EPIKART study, a pilot prospective comparative randomized. Henrotin Y, Berenbaum F, Chevalier X, Marty M, Richette P, Rannou F. BMC Musculoskelet Disord. 2017;18:222. doi: 10.1186/s12891-017-1585-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Comparison of two hyaluronic acid formulations for safety and efficacy (CHASE) study in knee osteoarthritis: a multicenter, randomized, double-blind, 26-week non-inferiority trial comparing Durolane to Artz. Zhang H, Zhang K, Zhang X, et al. Arthritis Res Ther. 2015;17:51. doi: 10.1186/s13075-015-0557-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.Origin and efficacy of hyaluronan injections in knee osteoarthritis: randomized, double-blind trial. Guo Y, Yang P, Liu L. Med Sci Monit. 2018;24:4728–4737. doi: 10.12659/MSM.908797. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.Comparison of two different molecular weight intra-articular injections of hyaluronic acid for the treatment of knee osteoarthritis. Gigis I, Fotiadis E, Nenopoulos A, Tsitas K, Hatzokos I. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5074393/ Hippokratia. 2016;20:26–31. [PMC free article] [PubMed] [Google Scholar]
- 36.Efficacy and safety of single injection of cross-linked sodium hyaluronate vs. three injections of high molecular weight sodium hyaluronate for osteoarthritis of the knee: a double-blind, randomized, multi-center, non-inferiority study. Ha CW, Park YB, Choi CH, et al. BMC Musculoskelet Disord. 2017;18:223. doi: 10.1186/s12891-017-1591-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37.Safety and performance of Hydros and Hydros-TA for knee osteoarthritis: a prospective, multicenter, randomized, double-blind feasibility trial. Petrella RJ, Emans PJ, Alleyne J, Dellaert F, Gill DP, Maroney M. BMC Musculoskelet Disord. 2015;16:57. doi: 10.1186/s12891-015-0513-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38.Viscosupplementation improves pain, function and muscle strength, but not proprioception, in patients with knee osteoarthritis: a prospective randomized trial. Maia PA, Cossich VR, Salles-Neto JI, Aguiar DP, de Sousa EB. Clinics (Sao Paulo) 2019;74:0. doi: 10.6061/clinics/2019/e1207. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39.A double blind randomized active-controlled clinical trial on the intra-articular use of Md-Knee versus sodium hyaluronate in patients with knee osteoarthritis ("Joint") Martin Martin LS, Massafra U, Bizzi E, Migliore A. BMC Musculoskelet Disord. 2016;17:94. doi: 10.1186/s12891-016-0948-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40.The comparison of knee osteoarthritis treatment with single-dose bone marrow-derived mononuclear cells vs. hyaluronic acid injections. Goncars V, Jakobsons E, Blums K, et al. Medicina (Kaunas) 2017;53:101–108. doi: 10.1016/j.medici.2017.02.002. [DOI] [PubMed] [Google Scholar]
- 41.Umbilical cord-derived mesenchymal stromal cells (MSCs) for knee osteoarthritis: repeated MSC dosing is superior to a single MSC dose and to hyaluronic acid in a controlled randomized phase I/II trial. Matas J, Orrego M, Amenabar D, et al. Stem Cells Transl Med. 2019;8:215–224. doi: 10.1002/sctm.18-0053. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42.Intra-articular injection of two different doses of autologous bone marrow mesenchymal stem cells versus hyaluronic acid in the treatment of knee osteoarthritis: multicenter randomized controlled clinical trial (phase I/II) Lamo-Espinosa JM, Mora G, Blanco JF, et al. J Transl Med. 2016;14:246. doi: 10.1186/s12967-016-0998-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43.Intra-articular ozone or hyaluronic acid injection: which one is superior in patients with knee osteoarthritis? A 6-month randomized clinical trial. Raeissadat SA, Rayegani SM, Forogh B, Abadi PH, Moridnia M, Dehgolan SR. J Pain Res. 2018;11:111–117. doi: 10.2147/JPR.S142755. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 44.Efficacy and safety of intra-articular injections of hyaluronic acid combined with polydeoxyribonucleotide in the treatment of knee osteoarthritis. Yoon S, Kang JJ, Kim J, Park S, Kim JM. Ann Rehabil Med. 2019;43:204–214. doi: 10.5535/arm.2019.43.2.204. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45.Platelet-rich plasma-derived growth factor vs hyaluronic acid injection in the individuals with knee osteoarthritis: a one year randomized clinical trial. Raeissadat SA, Gharooee Ahangar A, Rayegani SM, Minator Sajjadi M, Ebrahimpour A, Yavari P. J Pain Res. 2020;13:1699–1711. doi: 10.2147/JPR.S210715. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 46.Intra-articular injections of platelet-rich plasma versus hyaluronic acid in the treatment of osteoarthritic knee pain: a randomized clinical trial in the context of the Spanish national health care system. Montañez-Heredia E, Irízar S, Huertas PJ, et al. Int J Mol Sci. 2016;17:1064. doi: 10.3390/ijms17071064. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 47.Efficacy of intra-articular injection of a newly developed plasma rich in growth factor (PRGF) versus hyaluronic acid on pain and function of patients with knee osteoarthritis: a single-blinded randomized clinical trial. Raeissadat SA, Rayegani SM, Ahangar AG, Abadi PH, Mojgani P, Ahangar OG. Clin Med Insights Arthritis Musculoskelet Disord. 2017;10:1179544117733452. doi: 10.1177/1179544117733452. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 48.A randomized controlled single-blind study demonstrating superiority of amniotic suspension allograft injection over hyaluronic acid and saline control for modification of knee osteoarthritis symptoms. Farr J, Gomoll AH, Yanke AB, Strauss EJ, Mowry KC. J Knee Surg. 2019;32:1143–1154. doi: 10.1055/s-0039-1696672. [DOI] [PubMed] [Google Scholar]
- 49.Effectiveness of intra-articular injections of sodium hyaluronate-chondroitin sulfate in knee osteoarthritis: a multicenter prospective study. Rivera F, Bertignone L, Grandi G, et al. J Orthop Traumatol. 2016;17:27–33. doi: 10.1007/s10195-015-0388-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 50.Comparison of intra-articular injection of hyaluronic acid and N -acetyl cysteine in the treatment of knee osteoarthritis: a pilot study. Ozcamdalli M, Misir A, Kizkapan TB, Uzun E, Duygulu F, Yazici C, Kafadar IH. Cartilage. 2019;32:1143–1154. doi: 10.1177/1947603516675915. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 51.Efficacy and safety of diclofenac-hyaluronate conjugate (diclofenac etalhyaluronate) for knee osteoarthritis: a randomized phase III trial in Japan. Nishida Y, Kano K, Nobuoka Y, Seo T. Arthritis Rheumatol. 2021;73:1646–1655. doi: 10.1002/art.41725. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 52.Randomised, double-blind comparison of a fixed co-formulation of intra-articular polynucleotides and hyaluronic acid versus hyaluronic acid alone in the treatment of knee osteoarthritis: two-year follow-up. Stagni C, Rocchi M, Mazzotta A, et al. BMC Musculoskelet Disord. 2021;22:773. doi: 10.1186/s12891-021-04648-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 53.Does hyaluronic acid injection prevent the progression of knee osteoarthritis? Miyazaki T, Sakamoto T, Aoki N, Nakajima H, Oki H, Matsumine A. Osteoarthr Cartil. 2020;28:500. [Google Scholar]
- 54.Can combined use of low-level lasers and hyaluronic acid injections prolong the longevity of degenerative knee joints? Ip D, Fu NY. Clin Interv Aging. 2015;10:1255–1258. doi: 10.2147/CIA.S86907. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 55.Evidence for safety of retreatment with a single intra-articular injection of Gel-200 for treatment of osteoarthritis of the knee from the double-blind pivotal and open-label retreatment clinical trials. Strand V, Lim S, Takamura J. BMC Musculoskelet Disord. 2016;17:240. doi: 10.1186/s12891-016-1101-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 56.Intra-articular injection of photo-activated platelet-rich plasma in patients with knee osteoarthritis: a double-blind, randomized controlled pilot study. Paterson KL, Nicholls M, Bennell KL, Bates D. BMC Musculoskelet Disord. 2016;17:67. doi: 10.1186/s12891-016-0920-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 57.Hyaluronic acid versus platelet-rich plasma: a prospective, double-blind randomized controlled trial comparing clinical outcomes and effects on intra-articular biology for the treatment of knee osteoarthritis. Cole BJ, Karas V, Hussey K, Pilz K, Fortier LA. Am J Sports Med. 2017;45:339–346. doi: 10.1177/0363546516665809. [DOI] [PubMed] [Google Scholar]
- 58.Randomized controlled trial comparing hyaluronic acid, platelet-rich plasma and the combination of both in the treatment of mild and moderate osteoarthritis of the knee - letter to the editor & author response. Patel S, Dhillon MS, Bansal T. J Stem Cells Regen Med. 2017;13:80–83. doi: 10.46582/jsrm.1302012. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 59.Hyaluronic acid versus platelet-rich plasma: a prospective, double-blind randomized controlled trial comparing clinical outcomes and effects on intra-articular biology for the treatment of knee osteoarthritis. Lee JK, Lee BY, Shin WY, An MJ, Jung KI, Yoon SR. Ann Rehabil Med. 2017;41:828–835. doi: 10.1177/0363546516665809. [DOI] [PubMed] [Google Scholar]
- 60.Randomized controlled trial comparing efficacy of conventional and new single larger dose of intra-articular viscosupplementation in management of knee osteoarthritis. Suppan VK, Wei CY, Siong TC, et al. J Orthop Surg (Hong Kong) 2017;25:2309499017731627. doi: 10.1177/2309499017731627. [DOI] [PubMed] [Google Scholar]
- 61.Clinical therapy of hyaluronic acid combined with platelet-rich plasma for the treatment of knee osteoarthritis. Yu W, Xu P, Huang G, Liu L. Exp Ther Med. 2018;16:2119–2125. doi: 10.3892/etm.2018.6412. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 62.Intra-articular injection of two different doses of autologous bone marrow mesenchymal stem cells versus hyaluronic acid in the treatment of knee osteoarthritis: long-term follow up of a multicenter randomized controlled clinical trial (phase I/II) Lamo-Espinosa JM, Mora G, Blanco JF, et al. J Transl Med. 2018;16:213. doi: 10.1186/s12967-018-1591-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 63.Intraarticular injection of a cross-linked sodium hyaluronate combined with triamcinolone hexacetonide (Cingal) to provide symptomatic relief of osteoarthritis of the knee: a randomized, double-blind, placebo-controlled multicenter clinical trial. Hangody L, Szody R, Lukasik P, et al. Cartilage. 2018;9:276–283. doi: 10.1177/1947603517703732. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 64.Intra-articular, single-shot co-injection of hyaluronic acid and corticosteroids in knee osteoarthritis: a randomized controlled trial. Wang SZ, Wu DY, Chang Q, Guo YD, Wang C, Fan WM. Exp Ther Med. 2018;16:1928–1934. doi: 10.3892/etm.2018.6371. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 65.Clinical and radiographic comparison of a single LP-PRP injection, a single hyaluronic acid injection and daily NSAID administration with a 52-week follow-up: a randomized controlled trial. Buendía-López D, Medina-Quirós M, Fernández-Villacañas Marín MÁ. J Orthop Traumatol. 2018;19:3. doi: 10.1186/s10195-018-0501-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 66.The effectiveness of high molecular weight hyaluronic acid for knee osteoarthritis in patients in the working age: a randomised controlled trial. Hermans J, Bierma-Zeinstra SM, Bos PK, Niesten DD, Verhaar JA, Reijman M. BMC Musculoskelet Disord. 2019;20:196. doi: 10.1186/s12891-019-2546-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 67.A single intra-articular injection of 2.0% non-chemically modified sodium hyaluronate vs 0.8% hylan G-F 20 in the treatment of symptomatic knee osteoarthritis: a 6-month, multicenter, randomized, controlled non-inferiority trial. Maheu E, Avouac B, Dreiser RL, Bardin T. PLoS One. 2019;14:0. doi: 10.1371/journal.pone.0226007. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 68.A single intra-articular injection of gel-200 for treatment of symptomatic osteoarthritis of the knee is more effective than phosphate buffered saline at 6 months: a subgroup analysis of a multicenter, randomized controlled trial. Takamura J, Seo T, Strand V. Cartilage. 2019;10:417–422. doi: 10.1177/1947603518768015. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 69.Single- and double-dose of platelet-rich plasma versus hyaluronic acid for treatment of knee osteoarthritis: a randomized controlled trial. Tavassoli M, Janmohammadi N, Hosseini A, Khafri S, Esmaeilnejad-Ganji SM. World J Orthop. 2019;10:310–326. doi: 10.5312/wjo.v10.i9.310. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 70.Platelet-rich plasma versus hyaluronic acid injections for the treatment of knee osteoarthritis: results at 5 years of a double-blind, randomized controlled trial. Di Martino A, Di Matteo B, Papio T, et al. Am J Sports Med. 2019;47:347–354. doi: 10.1177/0363546518814532. [DOI] [PubMed] [Google Scholar]
- 71.Efficacy of single high-molecular-weight versus triple low-molecular-weight hyaluronic acid intra-articular injection among knee osteoarthritis patients. Bahrami MH, Raeissadat SA, Cheraghi M, Rahimi-Dehgolan S, Ebrahimpour A. BMC Musculoskelet Disord. 2020;21:550. doi: 10.1186/s12891-020-03577-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 72.Comparison of the short-term results of single-dose intra-articular peptide with hyaluronic acid and platelet-rich plasma injections in knee osteoarthritis: a randomized study. Kesiktas FN, Dernek B, Sen EI, Albayrak HN, Aydin T, Yildiz M. Clin Rheumatol. 2020;39:3057–3064. doi: 10.1007/s10067-020-05121-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 73.Comparison of patient-reported outcomes of treatment with low- and intermediate molecular weight hyaluronic acid in Japanese patients with symptomatic knee osteoarthritis: a prospective, randomized, single-blind trial. Mochizuki T, Ikari K, Yano K, Okazaki K. Asia Pac J Sports Med Arthrosc Rehabil Technol. 2020;21:22–26. doi: 10.1016/j.asmart.2020.04.001. [DOI] [PMC free article] [PubMed] [Google Scholar]